Across TCGA pan-cancer cohorts, ZNF730 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated ZNF730 data layer compared with 23 for mass-spec protein.
The strongest signal is observed in breast invasive carcinoma (BRCA), where higher ZNF730 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF730 expression acts as an unfavorable survival marker.
BRCA, HNSC, and CHOL are the cancer types where ZNF730 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.